{
  "doc_id": "19",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "盘点降糖药物的中国指南/共识(上)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "盘点降糖药物的中国指南/共识(上)",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "1",
      "paragraph": "降糖药物大多基于纠正导致血糖升高的两个主要病理生理改变，即胰岛素抵抗和胰岛素分泌受损。根据作用机制的不同，降糖药可分为：促进胰岛素分泌为主要作用的药物，包括磺脲类、格列奈类、二肽基肽酶-4(DPP-4) 抑制剂、胰高血糖素样肽-1(GLP-1) 受体激动剂或胰岛素替代药物(即外源性胰岛素制剂)；通过其他机制降低血糖的药物，包括双胍类、噻唑烷二酮类、α-糖苷酶抑制剂、钠-葡萄糖共转运蛋白2(SGLT-2) 抑制剂。下面我们将逐类盘点近几年发布的相关指南或共识，如存在更新版，则仅讨论最新版本。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "降糖药物大多基于纠正导致血糖升高的两个主要病理生理改变，即胰岛素抵抗和胰岛素分泌受损。",
          "start_idx": 0,
          "end_idx": 43,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 29,
              "end_idx": 34
            },
            {
              "entity_id": "T1",
              "entity": "胰岛素分泌受损",
              "entity_type": "Pathogenesis",
              "start_idx": 35,
              "end_idx": 42
            },
            {
              "entity_id": "T2",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 12,
              "end_idx": 14
            },
            {
              "entity_id": "T3",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 14,
              "end_idx": 16
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "根据作用机制的不同，降糖药可分为：促进胰岛素分泌为主要作用的药物，包括磺脲类、格列奈类、二肽基肽酶-4(DPP-4) 抑制剂、胰高血糖素样肽-1(GLP-1) 受体激动剂或胰岛素替代药物(即外源性胰岛素制剂)；通过其他机制降低血糖的药物，包括双胍类、噻唑烷二酮类、α-糖苷酶抑制剂、钠-葡萄糖共转运蛋白2(SGLT-2) 抑制剂。",
          "start_idx": 43,
          "end_idx": 208,
          "entities": [
            {
              "entity_id": "T4",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 38
            },
            {
              "entity_id": "T5",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 43
            },
            {
              "entity_id": "T6",
              "entity": "二肽基肽酶-4(DPP-4) 抑制剂",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 62
            },
            {
              "entity_id": "T7",
              "entity": "胰高血糖素样肽-1(GLP-1) 受体激动剂",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 85
            },
            {
              "entity_id": "T8",
              "entity": "胰岛素替代药物(即外源性胰岛素制剂)",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 104
            },
            {
              "entity_id": "T9",
              "entity": "双胍类",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 124
            },
            {
              "entity_id": "T10",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 125,
              "end_idx": 131
            },
            {
              "entity_id": "T11",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 132,
              "end_idx": 140
            },
            {
              "entity_id": "T12",
              "entity": "钠-葡萄糖共转运蛋白2(SGLT-2) 抑制剂",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 164
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "下面我们将逐类盘点近几年发布的相关指南或共识，如存在更新版，则仅讨论最新版本。",
          "start_idx": 208,
          "end_idx": 247,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": " ",
          "start_idx": 247,
          "end_idx": 248,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "2",
      "paragraph": "二甲双胍(资料来源：《二甲双胍临床应用专家共识(2016年版)》) ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍(资料来源：《二甲双胍临床应用专家共识(2016年版)》) ",
          "start_idx": 0,
          "end_idx": 34,
          "entities": [
            {
              "entity_id": "T13",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T14",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "3",
      "paragraph": "二甲双胍是一个在临床上已经应用了60年的老药，曾几经沉浮，目前国内外主要糖尿病指南均认可其核心地位，建议无论超重还是体重正常的2型糖尿病患者，除非存在禁忌证或无法耐受，否则都应从一开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍是一个在临床上已经应用了60年的老药，曾几经沉浮，目前国内外主要糖尿病指南均认可其核心地位，建议无论超重还是体重正常的2型糖尿病患者，除非存在禁忌证或无法耐受，否则都应从一开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍。",
          "start_idx": 0,
          "end_idx": 120,
          "entities": [
            {
              "entity_id": "T15",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T16",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 39
            },
            {
              "entity_id": "T17",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 56
            },
            {
              "entity_id": "T18",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 63,
              "end_idx": 68
            },
            {
              "entity_id": "T19",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99
            },
            {
              "entity_id": "T20",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 119
            },
            {
              "entity_id": "T21",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 63,
              "end_idx": 65
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R0",
              "head_entity_id": "T15",
              "tail_entity_id": "T16"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R1",
              "head_entity_id": "T19",
              "tail_entity_id": "T17"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R2",
              "head_entity_id": "T19",
              "tail_entity_id": "T18"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R3",
              "head_entity_id": "T21",
              "tail_entity_id": "T18"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": " ",
          "start_idx": 120,
          "end_idx": 121,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "4",
      "paragraph": "作用机制 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "作用机制 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "5",
      "paragraph": "二甲双胍改善高血糖的主要机制包括：(1)作用于肝脏，抑制糖异生，减少肝糖输出；(2)作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低游离脂肪酸，提高胰岛素敏感性，增加对葡萄糖的摄取和利用；(3)作用于肠道，抑制肠壁细胞摄取葡萄糖，提高胰高血糖素样肽-1(GLP-1) 水平。近年来研究者们更是发现二甲双胍可能具有改善肠道茵群、抗癌、抗衰老等更多”神奇“的作用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍改善高血糖的主要机制包括：(1)作用于肝脏，抑制糖异生，减少肝糖输出；(2)作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低游离脂肪酸，提高胰岛素敏感性，增加对葡萄糖的摄取和利用；(3)作用于肠道，抑制肠壁细胞摄取葡萄糖，提高胰高血糖素样肽-1(GLP-1) 水平。",
          "start_idx": 0,
          "end_idx": 139,
          "entities": [
            {
              "entity_id": "T22",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T23",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R4",
              "head_entity_id": "T22",
              "tail_entity_id": "T23"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "近年来研究者们更是发现二甲双胍可能具有改善肠道茵群、抗癌、抗衰老等更多”神奇“的作用。",
          "start_idx": 139,
          "end_idx": 182,
          "entities": [
            {
              "entity_id": "T24",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "6",
      "paragraph": "国内的多位内分泌、药学专家于2014年发布了第一版《二甲双胍临床应用专家共识》，基于这两年涌现的新证据，该共识于2016年进行了更新，从使用时机、剂量与疗效、安全性、特殊人群的使用以及降糖外作用等多个方面给出了指导建议。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "国内的多位内分泌、药学专家于2014年发布了第一版《二甲双胍临床应用专家共识》，基于这两年涌现的新证据，该共识于2016年进行了更新，从使用时机、剂量与疗效、安全性、特殊人群的使用以及降糖外作用等多个方面给出了指导建议。",
          "start_idx": 0,
          "end_idx": 110,
          "entities": [
            {
              "entity_id": "T25",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 30
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "7",
      "paragraph": "适用人群 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "适用人群 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "8",
      "paragraph": "应该说，二甲双胍是真正的糖尿病全程治疗药物，从糖尿病预防到糖尿病前期再到糖尿病的各个阶段。 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "应该说，二甲双胍是真正的糖尿病全程治疗药物，从糖尿病预防到糖尿病前期再到糖尿病的各个阶段。",
          "start_idx": 0,
          "end_idx": 45,
          "entities": [
            {
              "entity_id": "T26",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 8
            },
            {
              "entity_id": "T27",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 15
            },
            {
              "entity_id": "T28",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 26
            },
            {
              "entity_id": "T29",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 32
            },
            {
              "entity_id": "T30",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 39
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R5",
              "head_entity_id": "T26",
              "tail_entity_id": "T27"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": " ",
          "start_idx": 45,
          "end_idx": 46,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "9",
      "paragraph": "(1)2型糖尿病的一线首选和全程用药：在横向对比中，最佳有效剂量(2000毫克/天)二甲双胍治疗的降糖疗效要强于其他口服降糖药；在纵向对比中，与以其他口服降糖药物作为一线药物治疗的患者相比，以二甲双胍作为一线治疗的患者加用第二种口服降糖药或需要联合胰岛素治疗的时间最晚，以后需调整治疗方案的可能性也最低。二甲双胍减轻体重的这个“副作用”令其成为联合治疗中的“百搭药“。此外，二甲双胍还具有心血管保护作用，安全性和耐受性也很好，价格还不算贵。有这么多好处，也难怪该共识给出这样的建议，而且是最高级别的推荐——如无禁忌证，二甲双胍是治疗2型糖尿病的首选药物和联合治疗方案中的基础治疗药物，且应一直保留在糖尿病治疗方案中。记得在2007年版的《中国2型糖尿病防治指南》中还仅建议超重或肥胖的2型糖尿病患者将二甲双胍作为一线药物，此后的研究证据显示二甲双胍在正常体重/超重/肥胖的2型糖尿病患者中的疗效相当，体重并不是能否使用二甲双胍治疗的决定因素，所以早在2010年版的《中国2型糖尿病防治指南》中就已经开始给出与该共识类似的建议。\"",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)2型糖尿病的一线首选和全程用药：在横向对比中，最佳有效剂量(2000毫克/天)二甲双胍治疗的降糖疗效要强于其他口服降糖药；在纵向对比中，与以其他口服降糖药物作为一线药物治疗的患者相比，以二甲双胍作为一线治疗的患者加用第二种口服降糖药或需要联合胰岛素治疗的时间最晚，以后需调整治疗方案的可能性也最低。二甲双胍减轻体重的这个“副作用”令其成为联合治疗中的“百搭药“。此外，二甲双胍还具有心血管保护作用，安全性和耐受性也很好，价格还不算贵。有这么多好处，也难怪该共识给出这样的建议，而且是最高级别的推荐——如无禁忌证，二甲双胍是治疗2型糖尿病的首选药物和联合治疗方案中的基础治疗药物，且应一直保留在糖尿病治疗方案中。记得在2007年版的《中国2型糖尿病防治指南》中还仅建议超重或肥胖的2型糖尿病患者将二甲双胍作为一线药物，此后的研究证据显示二甲双胍在正常体重/超重/肥胖的2型糖尿病患者中的疗效相当，体重并不是能否使用二甲双胍治疗的决定因素，所以早在2010年版的《中国2型糖尿病防治指南》中就已经开始给出与该共识类似的建议。",
          "start_idx": 0,
          "end_idx": 463,
          "entities": [
            {
              "entity_id": "T31",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8
            },
            {
              "entity_id": "T32",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 46
            },
            {
              "entity_id": "T33",
              "entity": "2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 33,
              "end_idx": 41
            },
            {
              "entity_id": "T34",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 58,
              "end_idx": 60
            },
            {
              "entity_id": "T35",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 75,
              "end_idx": 77
            },
            {
              "entity_id": "T36",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 96,
              "end_idx": 100
            },
            {
              "entity_id": "T37",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 127
            },
            {
              "entity_id": "T38",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 152,
              "end_idx": 156
            },
            {
              "entity_id": "T39",
              "entity": "减轻体重",
              "entity_type": "ADE",
              "start_idx": 156,
              "end_idx": 160
            },
            {
              "entity_id": "T40",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 187,
              "end_idx": 191
            },
            {
              "entity_id": "T41",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 259,
              "end_idx": 263
            },
            {
              "entity_id": "T42",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 266,
              "end_idx": 271
            },
            {
              "entity_id": "T43",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 299,
              "end_idx": 302
            },
            {
              "entity_id": "T44",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 321,
              "end_idx": 326
            },
            {
              "entity_id": "T45",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 336,
              "end_idx": 338
            },
            {
              "entity_id": "T46",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 339,
              "end_idx": 341
            },
            {
              "entity_id": "T47",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 342,
              "end_idx": 347
            },
            {
              "entity_id": "T48",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 350,
              "end_idx": 354
            },
            {
              "entity_id": "T49",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 370,
              "end_idx": 374
            },
            {
              "entity_id": "T50",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 380,
              "end_idx": 382
            },
            {
              "entity_id": "T51",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 383,
              "end_idx": 385
            },
            {
              "entity_id": "T52",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 386,
              "end_idx": 391
            },
            {
              "entity_id": "T53",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 409,
              "end_idx": 413
            },
            {
              "entity_id": "T54",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 435,
              "end_idx": 440
            },
            {
              "entity_id": "T55",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 266,
              "end_idx": 268
            },
            {
              "entity_id": "T56",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 321,
              "end_idx": 323
            },
            {
              "entity_id": "T57",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 342,
              "end_idx": 344
            },
            {
              "entity_id": "T58",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 386,
              "end_idx": 388
            },
            {
              "entity_id": "T59",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 435,
              "end_idx": 437
            },
            {
              "entity_id": "T60",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 3,
              "end_idx": 5
            },
            {
              "entity_id": "T61",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 114,
              "end_idx": 116
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R6",
              "head_entity_id": "T32",
              "tail_entity_id": "T31"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R7",
              "head_entity_id": "T60",
              "tail_entity_id": "T31"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R8",
              "head_entity_id": "T33",
              "tail_entity_id": "T32"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R9",
              "head_entity_id": "T39",
              "tail_entity_id": "T38"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R10",
              "head_entity_id": "T41",
              "tail_entity_id": "T42"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R11",
              "head_entity_id": "T55",
              "tail_entity_id": "T42"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R12",
              "head_entity_id": "T56",
              "tail_entity_id": "T44"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R13",
              "head_entity_id": "T48",
              "tail_entity_id": "T45"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R14",
              "head_entity_id": "T48",
              "tail_entity_id": "T46"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R15",
              "head_entity_id": "T48",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R16",
              "head_entity_id": "T57",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R17",
              "head_entity_id": "T49",
              "tail_entity_id": "T50"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R18",
              "head_entity_id": "T49",
              "tail_entity_id": "T51"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R19",
              "head_entity_id": "T49",
              "tail_entity_id": "T52"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R20",
              "head_entity_id": "T58",
              "tail_entity_id": "T52"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R21",
              "head_entity_id": "T59",
              "tail_entity_id": "T54"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "\"",
          "start_idx": 463,
          "end_idx": 464,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "10",
      "paragraph": "(2)2型糖尿病预防用药：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物，能有效降低糖尿病前期人群发生2型糖尿病的风险，且具有良好的耐受性和长期有效性。不过在我国，预防糖尿病还不是二甲双胍的适应证，所以该共识也无法给出明确建议。但是，共识中提到，基于各国的大型研究结果，国际糖尿病联盟(IDF)2012年全球2型糖尿病指南推荐，预防糖尿病最好起始生活方式干预；对于空腹血糖受损(IFG)、年龄<60岁的肥胖人群，可给予二甲双胍干预；并建议糖尿病前期人群应起始生活方式干预，对生活方式不能有效控制血糖的患者，给予二甲双胍可有效预防糖尿病(属于超药品说明书用药——本刊注)，接受二甲双胍干预的患者应限于有预防糖尿病意愿、有很好的治疗依从性并有条件按照医嘱定期接受糖代谢评估的糖尿病前期个体。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)2型糖尿病预防用药：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物，能有效降低糖尿病前期人群发生2型糖尿病的风险，且具有良好的耐受性和长期有效性。不过在我国，预防糖尿病还不是二甲双胍的适应证，所以该共识也无法给出明确建议。但是，共识中提到，基于各国的大型研究结果，国际糖尿病联盟(IDF)2012年全球2型糖尿病指南推荐，预防糖尿病最好起始生活方式干预；对于空腹血糖受损(IFG)、年龄<60岁的肥胖人群，可给予二甲双胍干预；并建议糖尿病前期人群应起始生活方式干预，对生活方式不能有效控制血糖的患者，给予二甲双胍可有效预防糖尿病(属于超药品说明书用药——本刊注)，接受二甲双胍干预的患者应限于有预防糖尿病意愿、有很好的治疗依从性并有条件按照医嘱定期接受糖代谢评估的糖尿病前期个体。",
          "start_idx": 0,
          "end_idx": 348,
          "entities": [
            {
              "entity_id": "T62",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8
            },
            {
              "entity_id": "T63",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 3,
              "end_idx": 5
            },
            {
              "entity_id": "T64",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17
            },
            {
              "entity_id": "T65",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 30
            },
            {
              "entity_id": "T66",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 36
            },
            {
              "entity_id": "T67",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 50
            },
            {
              "entity_id": "T68",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 61
            },
            {
              "entity_id": "T69",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 56,
              "end_idx": 58
            },
            {
              "entity_id": "T70",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 92
            },
            {
              "entity_id": "T71",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99
            },
            {
              "entity_id": "T72",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 145
            },
            {
              "entity_id": "T73",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 159,
              "end_idx": 164
            },
            {
              "entity_id": "T74",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 159,
              "end_idx": 161
            },
            {
              "entity_id": "T75",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 171,
              "end_idx": 174
            },
            {
              "entity_id": "T76",
              "entity": "空腹血糖受损(IFG)",
              "entity_type": "Disease",
              "start_idx": 187,
              "end_idx": 198
            },
            {
              "entity_id": "T77",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 206,
              "end_idx": 208
            },
            {
              "entity_id": "T78",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 214,
              "end_idx": 218
            },
            {
              "entity_id": "T79",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 224,
              "end_idx": 227
            },
            {
              "entity_id": "T80",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 252,
              "end_idx": 254
            },
            {
              "entity_id": "T81",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 260,
              "end_idx": 264
            },
            {
              "entity_id": "T82",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 269,
              "end_idx": 272
            },
            {
              "entity_id": "T83",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 292,
              "end_idx": 296
            },
            {
              "entity_id": "T84",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 307,
              "end_idx": 310
            },
            {
              "entity_id": "T85",
              "entity": "糖代谢评估",
              "entity_type": "Test",
              "start_idx": 334,
              "end_idx": 339
            },
            {
              "entity_id": "T86",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 340,
              "end_idx": 343
            },
            {
              "entity_id": "T87",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 178,
              "end_idx": 184
            },
            {
              "entity_id": "T88",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 234,
              "end_idx": 240
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R22",
              "head_entity_id": "T63",
              "tail_entity_id": "T62"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R23",
              "head_entity_id": "T64",
              "tail_entity_id": "T65"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R24",
              "head_entity_id": "T69",
              "tail_entity_id": "T68"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R25",
              "head_entity_id": "T71",
              "tail_entity_id": "T70"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R26",
              "head_entity_id": "T74",
              "tail_entity_id": "T73"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R27",
              "head_entity_id": "T87",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R28",
              "head_entity_id": "T78",
              "tail_entity_id": "T76"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R29",
              "head_entity_id": "T78",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R30",
              "head_entity_id": "T88",
              "tail_entity_id": "T79"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R31",
              "head_entity_id": "T80",
              "tail_entity_id": "T79"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R32",
              "head_entity_id": "T81",
              "tail_entity_id": "T82"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R33",
              "head_entity_id": "T83",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R34",
              "head_entity_id": "T85",
              "tail_entity_id": "T86"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "11",
      "paragraph": "临床用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床用法",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "12",
      "paragraph": "(1)剂型选择：目前，国内单一成分的二甲双胍制剂包括普通片(250毫克/片、500毫克/片或850毫克/片)、缓释片或胶囊(500毫克/片或500毫克/胶囊)、肠溶片或胶囊(250毫克/片或250毫克/胶囊)等；复方制剂则包括二甲双胍与磺脲类、吡格列酮或DPP一4抑制剂组成的复方制剂。该共识指出：①各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同，普通片剂在胃内崩解释放，肠溶片从胃排空到肠道后崩解释放，缓释片和缓释胶囊在胃肠道内缓慢地溶出、释放，肠溶胶囊在肠道内溶出、释放；②普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之，因而每种制剂给药后血药浓度峰值、达峰时间、半衰期等参数存在一定差异，多剂量给药后的达稳时间也不一致；③缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性；④合格的药物制剂，在相同的给药剂量下，各种剂型问应具有生物等效性；⑤不同剂型的临床疗效是否一致，尚需更多的临床研究证实。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)剂型选择：目前，国内单一成分的二甲双胍制剂包括普通片(250毫克/片、500毫克/片或850毫克/片)、缓释片或胶囊(500毫克/片或500毫克/胶囊)、肠溶片或胶囊(250毫克/片或250毫克/胶囊)等；复方制剂则包括二甲双胍与磺脲类、吡格列酮或DPP一4抑制剂组成的复方制剂。",
          "start_idx": 0,
          "end_idx": 143,
          "entities": [
            {
              "entity_id": "T89",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 117
            },
            {
              "entity_id": "T90",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 121
            },
            {
              "entity_id": "T91",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 122,
              "end_idx": 126
            },
            {
              "entity_id": "T92",
              "entity": "DPP一4抑制剂",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 135
            },
            {
              "entity_id": "T94",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "该共识指出：①各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同，普通片剂在胃内崩解释放，肠溶片从胃排空到肠道后崩解释放，缓释片和缓释胶囊在胃肠道内缓慢地溶出、释放，肠溶胶囊在肠道内溶出、释放；②普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之，因而每种制剂给药后血药浓度峰值、达峰时间、半衰期等参数存在一定差异，多剂量给药后的达稳时间也不一致；③缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性；④合格的药物制剂，在相同的给药剂量下，各种剂型问应具有生物等效性；⑤不同剂型的临床疗效是否一致，尚需更多的临床研究证实。",
          "start_idx": 143,
          "end_idx": 435,
          "entities": [
            {
              "entity_id": "T93",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 215,
              "end_idx": 220
            },
            {
              "entity_id": "T95",
              "entity": "血药浓度",
              "entity_type": "Pathogenesis",
              "start_idx": 143,
              "end_idx": 147
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "13",
      "paragraph": "(2)使用方法：①用量临床研究显示，在500~2000毫克/天的剂量范围内，二甲双胍的降糖效果随剂量增加而增加，而当每日用量达到1000豪克后，胃肠道反应并未随剂量增加而加重。该共识推荐，二甲双胍起效的最小剂量为500毫克/天，成人可用的最大剂量为2550毫克/天，最佳有效剂量为2000毫克/天。大家看看是不是自己的二甲双胍用量远没有达到这个标准。②调量剂量调整遵循“小剂量起始，逐渐加量”的原则，开始时每日用量不超1000毫克，1~2周后加量至最大有效剂量2000毫克/天或最大耐受剂量。考虑药物的临床疗效及从患者依从性，可采用简化的剂量方案，建议起始500毫克，2次/天，如无明显胃肠道不良反应，随后可逐至1000，2次/天。③服法可在进餐时或餐后立即服用，缓释剂型1次/天，晚餐时或餐后立即服用。根据患者状况，当每日用量达到1500毫克后，可分为2~3次服用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)使用方法：①用量临床研究显示，在500~2000毫克/天的剂量范围内，二甲双胍的降糖效果随剂量增加而增加，而当每日用量达到1000豪克后，胃肠道反应并未随剂量增加而加重。该共识推荐，二甲双胍起效的最小剂量为500毫克/天，成人可用的最大剂量为2550毫克/天，最佳有效剂量为2000毫克/天。",
          "start_idx": 0,
          "end_idx": 149,
          "entities": [
            {
              "entity_id": "T96",
              "entity": "500~2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 19,
              "end_idx": 31
            },
            {
              "entity_id": "T97",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42
            },
            {
              "entity_id": "T98",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 72,
              "end_idx": 77
            },
            {
              "entity_id": "T99",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 94,
              "end_idx": 98
            },
            {
              "entity_id": "T100",
              "entity": "500毫克/天",
              "entity_type": "Amount",
              "start_idx": 106,
              "end_idx": 113
            },
            {
              "entity_id": "T101",
              "entity": "2550毫克/天",
              "entity_type": "Amount",
              "start_idx": 124,
              "end_idx": 132
            },
            {
              "entity_id": "T102",
              "entity": "2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 140,
              "end_idx": 148
            },
            {
              "entity_id": "T111",
              "entity": "每日用量达到1000豪克",
              "entity_type": "Amount",
              "start_idx": 58,
              "end_idx": 70
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R35",
              "head_entity_id": "T96",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R36",
              "head_entity_id": "T111",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R37",
              "head_entity_id": "T98",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R38",
              "head_entity_id": "T100",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R39",
              "head_entity_id": "T101",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R40",
              "head_entity_id": "T102",
              "tail_entity_id": "T99"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "大家看看是不是自己的二甲双胍用量远没有达到这个标准。",
          "start_idx": 149,
          "end_idx": 175,
          "entities": [
            {
              "entity_id": "T103",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "②调量剂量调整遵循“小剂量起始，逐渐加量”的原则，开始时每日用量不超1000毫克，1~2周后加量至最大有效剂量2000毫克/天或最大耐受剂量。",
          "start_idx": 175,
          "end_idx": 246,
          "entities": [
            {
              "entity_id": "T104",
              "entity": "2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 55,
              "end_idx": 63
            },
            {
              "entity_id": "T112",
              "entity": "每日用量不超1000毫克",
              "entity_type": "Amount",
              "start_idx": 28,
              "end_idx": 40
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "考虑药物的临床疗效及从患者依从性，可采用简化的剂量方案，建议起始500毫克，2次/天，如无明显胃肠道不良反应，随后可逐至1000，2次/天。",
          "start_idx": 246,
          "end_idx": 316,
          "entities": [
            {
              "entity_id": "T105",
              "entity": "500毫克",
              "entity_type": "Amount",
              "start_idx": 32,
              "end_idx": 37
            },
            {
              "entity_id": "T106",
              "entity": "2次/天",
              "entity_type": "Frequency",
              "start_idx": 38,
              "end_idx": 42
            },
            {
              "entity_id": "T107",
              "entity": "胃肠道不良反应",
              "entity_type": "ADE",
              "start_idx": 47,
              "end_idx": 54
            },
            {
              "entity_id": "T108",
              "entity": "1000",
              "entity_type": "Amount",
              "start_idx": 60,
              "end_idx": 64
            },
            {
              "entity_id": "T109",
              "entity": "2次/天",
              "entity_type": "Frequency",
              "start_idx": 65,
              "end_idx": 69
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "4",
          "sentence": "③服法可在进餐时或餐后立即服用，缓释剂型1次/天，晚餐时或餐后立即服用。",
          "start_idx": 316,
          "end_idx": 352,
          "entities": [
            {
              "entity_id": "T110",
              "entity": "1次/天",
              "entity_type": "Frequency",
              "start_idx": 20,
              "end_idx": 24
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "5",
          "sentence": "根据患者状况，当每日用量达到1500毫克后，可分为2~3次服用。",
          "start_idx": 352,
          "end_idx": 384,
          "entities": [
            {
              "entity_id": "T113",
              "entity": "每日用量达到1500毫克",
              "entity_type": "Amount",
              "start_idx": 8,
              "end_idx": 20
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "14",
      "paragraph": "(3)联合用药：将该共识的这部分内容概括一句话就是，二甲双胍可以和临床上现有的各种降糖药联用，而且还能减轻某些降糖药的副作用(α-糖苷酶抑制剂除外，两者联用有可能增加胃肠不适)，实现扬长避短的效果。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)联合用药：将该共识的这部分内容概括一句话就是，二甲双胍可以和临床上现有的各种降糖药联用，而且还能减轻某些降糖药的副作用(α-糖苷酶抑制剂除外，两者联用有可能增加胃肠不适)，实现扬长避短的效果。",
          "start_idx": 0,
          "end_idx": 99,
          "entities": [
            {
              "entity_id": "T114",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 30
            },
            {
              "entity_id": "T115",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 71
            },
            {
              "entity_id": "T116",
              "entity": "胃肠不适",
              "entity_type": "ADE",
              "start_idx": 83,
              "end_idx": 87
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R41",
              "head_entity_id": "T116",
              "tail_entity_id": "T114"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R42",
              "head_entity_id": "T116",
              "tail_entity_id": "T115"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "15",
      "paragraph": "(4)特殊情况：①尽管二甲双胍说明书上的禁忌一栏中列出了需要药物治疗的充血性心力衰竭，研究显示，二甲双胍本身并不会导致心衰，也不会对心衰患者造成不良影响，相反，甚至可能降低糖尿病患者心衰和死亡风险，提高伴心衰的糖尿病患者的存活率。所以，美国糖尿病协会(ADA)的糖尿病指南指出，如肾功能正常，二甲双胍可用于病情稳定的充血性心衰患者；欧洲版二甲双胍说明书中更是单春了慢性心衰的禁忌证。②年龄同样不是二甲双胍使用禁忌，而是要根据患者的肾功能情况而定，由于随着年龄增长，肾功能会逐渐下降，高龄患者使用二甲双胍时需定期监测肾功能。③二甲双胍可用于10岁及以上的2型糖尿病儿童青少年，且最高剂量不超过2000毫克/天，目前暂不推荐用于10岁以下的患儿④虽然国际多个学术组织推荐二甲双胍可用于妊娠糖尿病患者，但由于目前国内证据缺乏，我国药监部门尚未批准二甲双胍用于妊娠妇女。⑤尽管二甲双胍不经肝脏代谢，无肝脏毒性，但建议血清转氨酶超过3倍正常上限或有严重肝功能不全的患者避免使用二甲双胍，血清转氨酶轻度升高者使用时应密切监测肝功能。⑥二甲双胍本身不会对肾功能有影响，随着教育普及，公众对二甲双胍伤肾的错误认识已经得较普遍的纠正，近年来国内外的各大指南都将二甲双胍的使用范围放宽至轻中度肾功能不全患者，但中度肾功能不全患者应减少用量并停用治疗恶心、呕吐及脱水的药物。⑦肾功能正常者在造影前不必停用二甲双胍，但使用造影剂后应在医生的指导下停用48~72小时，复查肾功能正常后可继续用药；而肾功能异常者在使用造影剂及全身麻醉术前48小时时应暂停二甲双胍，之后还需停药48~72小时，复查肾功能正常后可继续用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)特殊情况：①尽管二甲双胍说明书上的禁忌一栏中列出了需要药物治疗的充血性心力衰竭，研究显示，二甲双胍本身并不会导致心衰，也不会对心衰患者造成不良影响，相反，甚至可能降低糖尿病患者心衰和死亡风险，提高伴心衰的糖尿病患者的存活率。所以，美国糖尿病协会(ADA)的糖尿病指南指出，如肾功能正常，二甲双胍可用于病情稳定的充血性心衰患者；欧洲版二甲双胍说明书中更是单春了慢性心衰的禁忌证。②年龄同样不是二甲双胍使用禁忌，而是要根据患者的肾功能情况而定，由于随着年龄增长，肾功能会逐渐下降，高龄患者使用二甲双胍时需定期监测肾功能。③二甲双胍可用于10岁及以上的2型糖尿病儿童青少年，且最高剂量不超过2000毫克/天，目前暂不推荐用于10岁以下的患儿④虽然国际多个学术组织推荐二甲双胍可用于妊娠糖尿病患者，但由于目前国内证据缺乏，我国药监部门尚未批准二甲双胍用于妊娠妇女。⑤尽管二甲双胍不经肝脏代谢，无肝脏毒性，但建议血清转氨酶超过3倍正常上限或有严重肝功能不全的患者避免使用二甲双胍，血清转氨酶轻度升高者使用时应密切监测肝功能。⑥二甲双胍本身不会对肾功能有影响，随着教育普及，公众对二甲双胍伤肾的错误认识已经得较普遍的纠正，近年来国内外的各大指南都将二甲双胍的使用范围放宽至轻中度肾功能不全患者，但中度肾功能不全患者应减少用量并停用治疗恶心、呕吐及脱水的药物。⑦肾功能正常者在造影前不必停用二甲双胍，但使用造影剂后应在医生的指导下停用48~72小时，复查肾功能正常后可继续用药；而肾功能异常者在使用造影剂及全身麻醉术前48小时时应暂停二甲双胍，之后还需停药48~72小时，复查肾功能正常后可继续用药。",
          "start_idx": 0,
          "end_idx": 696,
          "entities": [
            {
              "entity_id": "T117",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15
            },
            {
              "entity_id": "T118",
              "entity": "充血性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 42
            },
            {
              "entity_id": "T119",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 52
            },
            {
              "entity_id": "T120",
              "entity": "心衰",
              "entity_type": "ADE",
              "start_idx": 59,
              "end_idx": 61
            },
            {
              "entity_id": "T121",
              "entity": "心衰",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 68
            },
            {
              "entity_id": "T122",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 66,
              "end_idx": 67
            },
            {
              "entity_id": "T123",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 89
            },
            {
              "entity_id": "T124",
              "entity": "心衰",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 93
            },
            {
              "entity_id": "T125",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 91,
              "end_idx": 92
            },
            {
              "entity_id": "T126",
              "entity": "心衰",
              "entity_type": "Disease",
              "start_idx": 102,
              "end_idx": 104
            },
            {
              "entity_id": "T127",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 102,
              "end_idx": 103
            },
            {
              "entity_id": "T128",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 108
            },
            {
              "entity_id": "T129",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 120,
              "end_idx": 123
            },
            {
              "entity_id": "T130",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 131,
              "end_idx": 134
            },
            {
              "entity_id": "T131",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 150
            },
            {
              "entity_id": "T132",
              "entity": "充血性心衰",
              "entity_type": "Disease",
              "start_idx": 158,
              "end_idx": 163
            },
            {
              "entity_id": "T133",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 161,
              "end_idx": 162
            },
            {
              "entity_id": "T134",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 173
            },
            {
              "entity_id": "T135",
              "entity": "慢性心衰",
              "entity_type": "Disease",
              "start_idx": 182,
              "end_idx": 186
            },
            {
              "entity_id": "T136",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 198,
              "end_idx": 202
            },
            {
              "entity_id": "T137",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 247,
              "end_idx": 251
            },
            {
              "entity_id": "T138",
              "entity": "监测肾功能",
              "entity_type": "Test",
              "start_idx": 255,
              "end_idx": 260
            },
            {
              "entity_id": "T139",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 262,
              "end_idx": 266
            },
            {
              "entity_id": "T140",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 276,
              "end_idx": 281
            },
            {
              "entity_id": "T141",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 276,
              "end_idx": 278
            },
            {
              "entity_id": "T142",
              "entity": "2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 295,
              "end_idx": 303
            },
            {
              "entity_id": "T143",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 333,
              "end_idx": 337
            },
            {
              "entity_id": "T144",
              "entity": "妊娠糖尿病",
              "entity_type": "Disease",
              "start_idx": 340,
              "end_idx": 345
            },
            {
              "entity_id": "T145",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 370,
              "end_idx": 374
            },
            {
              "entity_id": "T146",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 384,
              "end_idx": 388
            },
            {
              "entity_id": "T147",
              "entity": "肝脏毒性",
              "entity_type": "ADE",
              "start_idx": 396,
              "end_idx": 400
            },
            {
              "entity_id": "T148",
              "entity": "血清转氨酶",
              "entity_type": "Test_items",
              "start_idx": 404,
              "end_idx": 409
            },
            {
              "entity_id": "T149",
              "entity": "超过3倍正常上限",
              "entity_type": "Test_Value",
              "start_idx": 409,
              "end_idx": 417
            },
            {
              "entity_id": "T150",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 419,
              "end_idx": 421
            },
            {
              "entity_id": "T151",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 421,
              "end_idx": 426
            },
            {
              "entity_id": "T152",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 421,
              "end_idx": 422
            },
            {
              "entity_id": "T153",
              "entity": "血清转氨酶",
              "entity_type": "Test_items",
              "start_idx": 438,
              "end_idx": 443
            },
            {
              "entity_id": "T154",
              "entity": "轻度升高",
              "entity_type": "Test_Value",
              "start_idx": 443,
              "end_idx": 447
            },
            {
              "entity_id": "T155",
              "entity": "监测肝功能",
              "entity_type": "Test",
              "start_idx": 454,
              "end_idx": 459
            },
            {
              "entity_id": "T156",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 461,
              "end_idx": 465
            },
            {
              "entity_id": "T157",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 487,
              "end_idx": 491
            },
            {
              "entity_id": "T158",
              "entity": "伤肾",
              "entity_type": "ADE",
              "start_idx": 491,
              "end_idx": 493
            },
            {
              "entity_id": "T159",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 521,
              "end_idx": 525
            },
            {
              "entity_id": "T160",
              "entity": "轻中度",
              "entity_type": "Level",
              "start_idx": 533,
              "end_idx": 536
            },
            {
              "entity_id": "T161",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 536,
              "end_idx": 541
            },
            {
              "entity_id": "T162",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 536,
              "end_idx": 537
            },
            {
              "entity_id": "T163",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 545,
              "end_idx": 547
            },
            {
              "entity_id": "T164",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 547,
              "end_idx": 552
            },
            {
              "entity_id": "T165",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 547,
              "end_idx": 548
            },
            {
              "entity_id": "T166",
              "entity": "造影",
              "entity_type": "Test",
              "start_idx": 584,
              "end_idx": 586
            },
            {
              "entity_id": "T167",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 591,
              "end_idx": 595
            },
            {
              "entity_id": "T168",
              "entity": "造影剂",
              "entity_type": "Drug",
              "start_idx": 599,
              "end_idx": 602
            },
            {
              "entity_id": "T169",
              "entity": "肾功能异常",
              "entity_type": "Disease",
              "start_idx": 636,
              "end_idx": 641
            },
            {
              "entity_id": "T170",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 636,
              "end_idx": 637
            },
            {
              "entity_id": "T171",
              "entity": "造影剂",
              "entity_type": "Drug",
              "start_idx": 645,
              "end_idx": 648
            },
            {
              "entity_id": "T172",
              "entity": "全身麻醉",
              "entity_type": "Operation",
              "start_idx": 649,
              "end_idx": 653
            },
            {
              "entity_id": "T173",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 663,
              "end_idx": 667
            },
            {
              "entity_id": "T174",
              "entity": "复查肾功能",
              "entity_type": "Test",
              "start_idx": 682,
              "end_idx": 687
            },
            {
              "entity_id": "T175",
              "entity": "复查肾功能",
              "entity_type": "Test",
              "start_idx": 621,
              "end_idx": 626
            },
            {
              "entity_id": "T176",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 38,
              "end_idx": 39
            },
            {
              "entity_id": "T177",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 184,
              "end_idx": 185
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R43",
              "head_entity_id": "T176",
              "tail_entity_id": "T118"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R44",
              "head_entity_id": "T122",
              "tail_entity_id": "T121"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R45",
              "head_entity_id": "T125",
              "tail_entity_id": "T124"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R46",
              "head_entity_id": "T127",
              "tail_entity_id": "T126"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R47",
              "head_entity_id": "T131",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R48",
              "head_entity_id": "T177",
              "tail_entity_id": "T135"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R49",
              "head_entity_id": "T139",
              "tail_entity_id": "T140"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R50",
              "head_entity_id": "T142",
              "tail_entity_id": "T139"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R51",
              "head_entity_id": "T141",
              "tail_entity_id": "T140"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R52",
              "head_entity_id": "T143",
              "tail_entity_id": "T144"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R53",
              "head_entity_id": "T152",
              "tail_entity_id": "T151"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R54",
              "head_entity_id": "T159",
              "tail_entity_id": "T161"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R55",
              "head_entity_id": "T162",
              "tail_entity_id": "T161"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R56",
              "head_entity_id": "T165",
              "tail_entity_id": "T164"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R57",
              "head_entity_id": "T170",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R58",
              "head_entity_id": "T171",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R59",
              "head_entity_id": "T172",
              "tail_entity_id": "T169"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "16",
      "paragraph": "(5)药物相互作用：①氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯蝶啶、甲氧苄氨嘧啶和万古霉素等药物会影响肾功能或二甲双胍分布，因此建议密切监测血糖并调整二甲双胍和/或其他药物的剂量。②同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物时，也应密切监测血糖，这些药物停用后，则要密切注意低血糖。③二甲双胍有增加华法林的抗凝血倾向。④树脂类药物，如苏合香、血竭、乳香等中药与二甲双胍合用会减少其吸收。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(5)药物相互作用：①氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯蝶啶、甲氧苄氨嘧啶和万古霉素等药物会影响肾功能或二甲双胍分布，因此建议密切监测血糖并调整二甲双胍和/或其他药物的剂量。②同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物时，也应密切监测血糖，这些药物停用后，则要密切注意低血糖。③二甲双胍有增加华法林的抗凝血倾向。",
          "start_idx": 0,
          "end_idx": 230,
          "entities": [
            {
              "entity_id": "T178",
              "entity": "氨氯吡咪",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15
            },
            {
              "entity_id": "T179",
              "entity": "地高辛",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 19
            },
            {
              "entity_id": "T180",
              "entity": "吗啡",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 22
            },
            {
              "entity_id": "T181",
              "entity": "普鲁卡因胺",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 28
            },
            {
              "entity_id": "T182",
              "entity": "奎尼丁",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 32
            },
            {
              "entity_id": "T183",
              "entity": "奎宁",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 35
            },
            {
              "entity_id": "T184",
              "entity": "雷尼替丁",
              "entity_type": "Drug",
              "start_idx": 36,
              "end_idx": 40
            },
            {
              "entity_id": "T185",
              "entity": "氨苯蝶啶",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 45
            },
            {
              "entity_id": "T186",
              "entity": "甲氧苄氨嘧啶",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 52
            },
            {
              "entity_id": "T187",
              "entity": "万古霉素",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T188",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 71
            },
            {
              "entity_id": "T189",
              "entity": "监测血糖",
              "entity_type": "Test_items",
              "start_idx": 80,
              "end_idx": 84
            },
            {
              "entity_id": "T190",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 87,
              "end_idx": 91
            },
            {
              "entity_id": "T191",
              "entity": "噻嗪类药物",
              "entity_type": "Drug",
              "start_idx": 107,
              "end_idx": 112
            },
            {
              "entity_id": "T192",
              "entity": "利尿剂",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 118
            },
            {
              "entity_id": "T193",
              "entity": "糖皮质激素",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 124
            },
            {
              "entity_id": "T194",
              "entity": "吩噻嗪",
              "entity_type": "Drug",
              "start_idx": 125,
              "end_idx": 128
            },
            {
              "entity_id": "T195",
              "entity": "甲状腺制剂",
              "entity_type": "Drug",
              "start_idx": 129,
              "end_idx": 134
            },
            {
              "entity_id": "T196",
              "entity": "雌激素",
              "entity_type": "Drug",
              "start_idx": 135,
              "end_idx": 138
            },
            {
              "entity_id": "T197",
              "entity": "口服避孕药",
              "entity_type": "Drug",
              "start_idx": 139,
              "end_idx": 144
            },
            {
              "entity_id": "T198",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 139,
              "end_idx": 141
            },
            {
              "entity_id": "T199",
              "entity": "苯妥英",
              "entity_type": "Drug",
              "start_idx": 145,
              "end_idx": 148
            },
            {
              "entity_id": "T200",
              "entity": "烟碱酸",
              "entity_type": "Drug",
              "start_idx": 149,
              "end_idx": 152
            },
            {
              "entity_id": "T201",
              "entity": "拟交感神经药",
              "entity_type": "Drug",
              "start_idx": 153,
              "end_idx": 159
            },
            {
              "entity_id": "T202",
              "entity": "钙离子通道阻滞剂",
              "entity_type": "Drug",
              "start_idx": 160,
              "end_idx": 168
            },
            {
              "entity_id": "T203",
              "entity": "异烟肼",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 172
            },
            {
              "entity_id": "T204",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 176,
              "end_idx": 178
            },
            {
              "entity_id": "T205",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 178,
              "end_idx": 180
            },
            {
              "entity_id": "T206",
              "entity": "监测血糖",
              "entity_type": "Test_items",
              "start_idx": 189,
              "end_idx": 193
            },
            {
              "entity_id": "T207",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 208,
              "end_idx": 211
            },
            {
              "entity_id": "T208",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 213,
              "end_idx": 217
            },
            {
              "entity_id": "T209",
              "entity": "华法林",
              "entity_type": "Drug",
              "start_idx": 220,
              "end_idx": 223
            },
            {
              "entity_id": "T210",
              "entity": "抗凝血",
              "entity_type": "ADE",
              "start_idx": 224,
              "end_idx": 227
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R60",
              "head_entity_id": "T198",
              "tail_entity_id": "T197"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R61",
              "head_entity_id": "T210",
              "tail_entity_id": "T209"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "④树脂类药物，如苏合香、血竭、乳香等中药与二甲双胍合用会减少其吸收。",
          "start_idx": 230,
          "end_idx": 264,
          "entities": [
            {
              "entity_id": "T211",
              "entity": "苏合香",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 11
            },
            {
              "entity_id": "T212",
              "entity": "血竭",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 14
            },
            {
              "entity_id": "T213",
              "entity": "乳香",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 17
            },
            {
              "entity_id": "T214",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 25
            },
            {
              "entity_id": "T215",
              "entity": "树脂类药物",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 6
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "17",
      "paragraph": "磺脲类药物(资料来源：《磺脲类药物临床应用专家共识(2016年版)》)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物(资料来源：《磺脲类药物临床应用专家共识(2016年版)》)",
          "start_idx": 0,
          "end_idx": 35,
          "entities": [
            {
              "entity_id": "T216",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T217",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 17
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "18",
      "paragraph": "磺脲类药物正式用于糖尿病临床治疗也已经快60年了，目前仍是糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病指南中占据着非常重要的治疗地位。基于循证医学证据的进展，2004年版《磺脲类药物临床应用专家共识》在2016年得到更新。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物正式用于糖尿病临床治疗也已经快60年了，目前仍是糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病指南中占据着非常重要的治疗地位。",
          "start_idx": 0,
          "end_idx": 79,
          "entities": [
            {
              "entity_id": "T218",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T219",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12
            },
            {
              "entity_id": "T220",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 32
            },
            {
              "entity_id": "T221",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 43,
              "end_idx": 45
            },
            {
              "entity_id": "T222",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 63
            },
            {
              "entity_id": "T223",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 58,
              "end_idx": 60
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R62",
              "head_entity_id": "T218",
              "tail_entity_id": "T219"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R63",
              "head_entity_id": "T221",
              "tail_entity_id": "T218"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R64",
              "head_entity_id": "T223",
              "tail_entity_id": "T222"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "基于循证医学证据的进展，2004年版《磺脲类药物临床应用专家共识》在2016年得到更新。",
          "start_idx": 79,
          "end_idx": 123,
          "entities": [
            {
              "entity_id": "T224",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 24
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "19",
      "paragraph": "作用机制",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "作用机制",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "20",
      "paragraph": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，其中格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。②部分胰岛素增敏作用。试验表明，磺脲类药物可使外周葡萄糖利用率加平均增加近三分之一(29%)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，其中格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。",
          "start_idx": 0,
          "end_idx": 56,
          "entities": [
            {
              "entity_id": "T225",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T226",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10
            },
            {
              "entity_id": "T227",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 36
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R65",
              "head_entity_id": "T225",
              "tail_entity_id": "T226"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "②部分胰岛素增敏作用。",
          "start_idx": 56,
          "end_idx": 67,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "试验表明，磺脲类药物可使外周葡萄糖利用率加平均增加近三分之一(29%)。",
          "start_idx": 67,
          "end_idx": 103,
          "entities": [
            {
              "entity_id": "T228",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 10
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "21",
      "paragraph": "适用人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "适用人群",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "22",
      "paragraph": "尽管新型降糖药物不断出现，磺脲类药物以其临床应用经验丰富、疗效确切和价格低廉，无论是在国内还是国外，仍然被广泛应用，国内外的多个2型糖尿病指南也将其推荐为一线备选或二线降糖用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "尽管新型降糖药物不断出现，磺脲类药物以其临床应用经验丰富、疗效确切和价格低廉，无论是在国内还是国外，仍然被广泛应用，国内外的多个2型糖尿病指南也将其推荐为一线备选或二线降糖用药。",
          "start_idx": 0,
          "end_idx": 89,
          "entities": [
            {
              "entity_id": "T229",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 18
            },
            {
              "entity_id": "T230",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 64,
              "end_idx": 69
            },
            {
              "entity_id": "T231",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 64,
              "end_idx": 66
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R66",
              "head_entity_id": "T229",
              "tail_entity_id": "T230"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R67",
              "head_entity_id": "T231",
              "tail_entity_id": "T230"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "23",
      "paragraph": "(1)一线备选：尽管二甲双胍被作为一线用药，但当患者无法耐受二甲双胍治疗或是存在禁忌证时，可考虑将磺脲类药物作为一线用药。该共识还指出，对于新诊断的糖化血红蛋白>7.5%的2型糖尿病患者，可选择作用机制互补的两种降糖药物联合应用，结合中国国情和患者特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)一线备选：尽管二甲双胍被作为一线用药，但当患者无法耐受二甲双胍治疗或是存在禁忌证时，可考虑将磺脲类药物作为一线用药。该共识还指出，对于新诊断的糖化血红蛋白>7.5%的2型糖尿病患者，可选择作用机制互补的两种降糖药物联合应用，结合中国国情和患者特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。",
          "start_idx": 0,
          "end_idx": 151,
          "entities": [
            {
              "entity_id": "T232",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14
            },
            {
              "entity_id": "T233",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 34
            },
            {
              "entity_id": "T234",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 54
            },
            {
              "entity_id": "T235",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 74,
              "end_idx": 80
            },
            {
              "entity_id": "T236",
              "entity": ">7.5%",
              "entity_type": "Test_Value",
              "start_idx": 80,
              "end_idx": 85
            },
            {
              "entity_id": "T237",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 91
            },
            {
              "entity_id": "T238",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 86,
              "end_idx": 88
            },
            {
              "entity_id": "T239",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 132
            },
            {
              "entity_id": "T240",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 138
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R68",
              "head_entity_id": "T238",
              "tail_entity_id": "T237"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "24",
      "paragraph": "(2)二线用药：当二甲双胍最佳有效剂量单药治疗仍无法控糖达标时，需增加其他类型降糖药，磺脲类药物是备选之一。需要指出的是，尽管磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。相比于传统磺脲类药物(如氯磺丙脲、格列本脲)，新型磺脲类药物(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小，而且通过与二甲双胍、阿卡波糖、SGLT一2抑制剂等具有减轻体重作用的药物联用，能够减少磺脲类药物的体重增加风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)二线用药：当二甲双胍最佳有效剂量单药治疗仍无法控糖达标时，需增加其他类型降糖药，磺脲类药物是备选之一。需要指出的是，尽管磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。",
          "start_idx": 0,
          "end_idx": 95,
          "entities": [
            {
              "entity_id": "T241",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13
            },
            {
              "entity_id": "T242",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 48
            },
            {
              "entity_id": "T243",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 68
            },
            {
              "entity_id": "T244",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 73,
              "end_idx": 77
            },
            {
              "entity_id": "T245",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 81
            },
            {
              "entity_id": "T246",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 82,
              "end_idx": 84
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R69",
              "head_entity_id": "T244",
              "tail_entity_id": "T243"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "相比于传统磺脲类药物(如氯磺丙脲、格列本脲)，新型磺脲类药物(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小，而且通过与二甲双胍、阿卡波糖、SGLT一2抑制剂等具有减轻体重作用的药物联用，能够减少磺脲类药物的体重增加风险。",
          "start_idx": 95,
          "end_idx": 211,
          "entities": [
            {
              "entity_id": "T247",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 10
            },
            {
              "entity_id": "T248",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 16
            },
            {
              "entity_id": "T249",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21
            },
            {
              "entity_id": "T250",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 30
            },
            {
              "entity_id": "T251",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 36
            },
            {
              "entity_id": "T252",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 49
            },
            {
              "entity_id": "T253",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 69
            },
            {
              "entity_id": "T254",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 74
            },
            {
              "entity_id": "T255",
              "entity": "SGLT一2抑制剂",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 84
            },
            {
              "entity_id": "T256",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 108
            },
            {
              "entity_id": "T257",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 109,
              "end_idx": 113
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R70",
              "head_entity_id": "T257",
              "tail_entity_id": "T256"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "25",
      "paragraph": "临床用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床用法",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "26",
      "paragraph": "(1)药物选择：从磺脲类药物的降糖机制不难看出，患者需要有一定的胰岛功能才能起效，所以糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物的疗效会更好。早期磺脲类药物甲苯磺丁脲和氯磺丙脲已基本退出临床，目前临床常用的磺脲类药物包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲等。格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短，适用于餐后血糖升高为主的患者；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长，适用于以空腹血糖升高为主的患者或空腹、餐后血糖均高的患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)药物选择：从磺脲类药物的降糖机制不难看出，患者需要有一定的胰岛功能才能起效，所以糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物的疗效会更好。",
          "start_idx": 0,
          "end_idx": 79,
          "entities": [
            {
              "entity_id": "T258",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14
            },
            {
              "entity_id": "T259",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 46
            },
            {
              "entity_id": "T260",
              "entity": "饮食和运动干预",
              "entity_type": "Treatment",
              "start_idx": 55,
              "end_idx": 62
            },
            {
              "entity_id": "T261",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 72
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R71",
              "head_entity_id": "T260",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R72",
              "head_entity_id": "T261",
              "tail_entity_id": "T259"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "早期磺脲类药物甲苯磺丁脲和氯磺丙脲已基本退出临床，目前临床常用的磺脲类药物包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲等。",
          "start_idx": 79,
          "end_idx": 144,
          "entities": [
            {
              "entity_id": "T262",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T263",
              "entity": "甲苯磺丁脲",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 12
            },
            {
              "entity_id": "T264",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17
            },
            {
              "entity_id": "T265",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 37
            },
            {
              "entity_id": "T266",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 43
            },
            {
              "entity_id": "T267",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 48
            },
            {
              "entity_id": "T268",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53
            },
            {
              "entity_id": "T269",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58
            },
            {
              "entity_id": "T270",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短，适用于餐后血糖升高为主的患者；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长，适用于以空腹血糖升高为主的患者或空腹、餐后血糖均高的患者。",
          "start_idx": 144,
          "end_idx": 260,
          "entities": [
            {
              "entity_id": "T271",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T272",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9
            },
            {
              "entity_id": "T273",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 34
            },
            {
              "entity_id": "T274",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 34,
              "end_idx": 36
            },
            {
              "entity_id": "T275",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 46
            },
            {
              "entity_id": "T276",
              "entity": "格列吡嗪控释剂",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 54
            },
            {
              "entity_id": "T277",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 59
            },
            {
              "entity_id": "T278",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 67
            },
            {
              "entity_id": "T279",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 72
            },
            {
              "entity_id": "T280",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 91,
              "end_idx": 95
            },
            {
              "entity_id": "T281",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 95,
              "end_idx": 97
            },
            {
              "entity_id": "T282",
              "entity": "空腹、餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 103,
              "end_idx": 110
            },
            {
              "entity_id": "T283",
              "entity": "均高",
              "entity_type": "Test_Value",
              "start_idx": 110,
              "end_idx": 112
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "27",
      "paragraph": "(2)使用方法：磺脲类药物的降糖作用在常规剂量内呈剂量依赖性，且患者初始糖化血红蛋白水平越高，治疗后的降幅越大。由于低血糖是磺脲类药物最常见的不良反应，所以宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。任何一种磺脲类药物的每日用量都不应超过其最大剂量。常用磺脲类药物的用法见表1。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)使用方法：磺脲类药物的降糖作用在常规剂量内呈剂量依赖性，且患者初始糖化血红蛋白水平越高，治疗后的降幅越大。由于低血糖是磺脲类药物最常见的不良反应，所以宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。",
          "start_idx": 0,
          "end_idx": 113,
          "entities": [
            {
              "entity_id": "T284",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 13
            },
            {
              "entity_id": "T285",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 42
            },
            {
              "entity_id": "T286",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 58,
              "end_idx": 61
            },
            {
              "entity_id": "T287",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 62,
              "end_idx": 67
            },
            {
              "entity_id": "T288",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 88,
              "end_idx": 92
            },
            {
              "entity_id": "T291",
              "entity": "水平越高",
              "entity_type": "Test_Value",
              "start_idx": 42,
              "end_idx": 46
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R73",
              "head_entity_id": "T286",
              "tail_entity_id": "T287"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "任何一种磺脲类药物的每日用量都不应超过其最大剂量。",
          "start_idx": 113,
          "end_idx": 138,
          "entities": [
            {
              "entity_id": "T289",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "常用磺脲类药物的用法见表1。",
          "start_idx": 138,
          "end_idx": 152,
          "entities": [
            {
              "entity_id": "T290",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "28",
      "paragraph": "(3)联合用药：尽管磺脲类药物理论上可以和各种降糖药联用以获得更好的降糖效果，但正如之前提到的，考虑到磺脲类药物的低血糖和增重副作用，它更适合与二甲双胍、α一糖苷酶抑制剂等低血糖风险低且具有减重作用的药物联用。需要特别指出的是，尽管通常不推荐磺脲类药物联合胰岛素治疗，但胰岛细胞尚有部分分泌功能的2型糖尿病患者可考虑使用磺脲类药物联合基础胰岛素治疗，不过应特别注意饮食和运动量，以及体重增加和低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)联合用药：尽管磺脲类药物理论上可以和各种降糖药联用以获得更好的降糖效果，但正如之前提到的，考虑到磺脲类药物的低血糖和增重副作用，它更适合与二甲双胍、α一糖苷酶抑制剂等低血糖风险低且具有减重作用的药物联用。需要特别指出的是，尽管通常不推荐磺脲类药物联合胰岛素治疗，但胰岛细胞尚有部分分泌功能的2型糖尿病患者可考虑使用磺脲类药物联合基础胰岛素治疗，不过应特别注意饮食和运动量，以及体重增加和低血糖。",
          "start_idx": 0,
          "end_idx": 200,
          "entities": [
            {
              "entity_id": "T292",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 15
            },
            {
              "entity_id": "T293",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 56
            },
            {
              "entity_id": "T294",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 57,
              "end_idx": 60
            },
            {
              "entity_id": "T295",
              "entity": "增重",
              "entity_type": "ADE",
              "start_idx": 61,
              "end_idx": 63
            },
            {
              "entity_id": "T296",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 72,
              "end_idx": 76
            },
            {
              "entity_id": "T297",
              "entity": "α一糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 85
            },
            {
              "entity_id": "T298",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 126
            },
            {
              "entity_id": "T299",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 128,
              "end_idx": 131
            },
            {
              "entity_id": "T300",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 148,
              "end_idx": 153
            },
            {
              "entity_id": "T301",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 148,
              "end_idx": 150
            },
            {
              "entity_id": "T302",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 160,
              "end_idx": 165
            },
            {
              "entity_id": "T303",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 172
            },
            {
              "entity_id": "T304",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 191,
              "end_idx": 195
            },
            {
              "entity_id": "T305",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 196,
              "end_idx": 199
            },
            {
              "entity_id": "T306",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 86,
              "end_idx": 89
            },
            {
              "entity_id": "T307",
              "entity": "注意饮食和运动量",
              "entity_type": "Treatment",
              "start_idx": 180,
              "end_idx": 188
            },
            {
              "entity_id": "T308",
              "entity": "减重",
              "entity_type": "ADE",
              "start_idx": 95,
              "end_idx": 97
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R74",
              "head_entity_id": "T294",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R75",
              "head_entity_id": "T295",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R76",
              "head_entity_id": "T301",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R77",
              "head_entity_id": "T302",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R78",
              "head_entity_id": "T303",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R79",
              "head_entity_id": "T307",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R80",
              "head_entity_id": "T304",
              "tail_entity_id": "T302"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R81",
              "head_entity_id": "T305",
              "tail_entity_id": "T302"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "29",
      "paragraph": "(4)特殊情况：①目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(ALT)>8~10倍参考值上限或ALT>3倍参考值上限且血清总胆红素(TBIL)>2倍参考值上限提示重度肝损害，应禁用磺脲类药物。②肾功能不全者禁用格列本脲，格列吡嗪、格列齐特、格列美脲可用于轻度肾功能不全患者，格列喹酮则可用于轻、中度肾功能不全患者。医生需要根据肾功能情况来确定如何调整治疗，见表2。③老年患者应重点考虑药物的低血糖风险，若既往有严重低血糖史、预期生存期较短或合并其他严重疾病，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖发生风险降至最小。④目前，所有磺脲类药物均未被中国食品药品监督管理局(CFDA)批准用于妊娠、儿童和青少年患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)特殊情况：①目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(ALT)>8~10倍参考值上限或ALT>3倍参考值上限且血清总胆红素(TBIL)>2倍参考值上限提示重度肝损害，应禁用磺脲类药物。②肾功能不全者禁用格列本脲，格列吡嗪、格列齐特、格列美脲可用于轻度肾功能不全患者，格列喹酮则可用于轻、中度肾功能不全患者。医生需要根据肾功能情况来确定如何调整治疗，见表2。③老年患者应重点考虑药物的低血糖风险，若既往有严重低血糖史、预期生存期较短或合并其他严重疾病，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖发生风险降至最小。",
          "start_idx": 0,
          "end_idx": 341,
          "entities": [
            {
              "entity_id": "T309",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 18
            },
            {
              "entity_id": "T310",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 23,
              "end_idx": 25
            },
            {
              "entity_id": "T311",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 30
            },
            {
              "entity_id": "T312",
              "entity": "丙氨酸氨基转移酶(ALT)",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 49
            },
            {
              "entity_id": "T313",
              "entity": ">8~10倍参考值上限",
              "entity_type": "Test_Value",
              "start_idx": 49,
              "end_idx": 60
            },
            {
              "entity_id": "T314",
              "entity": "ALT",
              "entity_type": "Test_items",
              "start_idx": 61,
              "end_idx": 64
            },
            {
              "entity_id": "T315",
              "entity": ">3倍参考值上限",
              "entity_type": "Test_Value",
              "start_idx": 64,
              "end_idx": 72
            },
            {
              "entity_id": "T316",
              "entity": "血清总胆红素(TBIL)",
              "entity_type": "Test_items",
              "start_idx": 73,
              "end_idx": 85
            },
            {
              "entity_id": "T317",
              "entity": ">2倍参考值上限",
              "entity_type": "Test_Value",
              "start_idx": 85,
              "end_idx": 93
            },
            {
              "entity_id": "T318",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 95,
              "end_idx": 97
            },
            {
              "entity_id": "T319",
              "entity": "肝损害",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 100
            },
            {
              "entity_id": "T320",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 97,
              "end_idx": 98
            },
            {
              "entity_id": "T321",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 109
            },
            {
              "entity_id": "T322",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 116
            },
            {
              "entity_id": "T323",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 111,
              "end_idx": 112
            },
            {
              "entity_id": "T324",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 123
            },
            {
              "entity_id": "T325",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 128
            },
            {
              "entity_id": "T326",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 129,
              "end_idx": 133
            },
            {
              "entity_id": "T327",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 138
            },
            {
              "entity_id": "T328",
              "entity": "轻度",
              "entity_type": "Level",
              "start_idx": 141,
              "end_idx": 143
            },
            {
              "entity_id": "T329",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 143,
              "end_idx": 148
            },
            {
              "entity_id": "T330",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 143,
              "end_idx": 144
            },
            {
              "entity_id": "T331",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 151,
              "end_idx": 155
            },
            {
              "entity_id": "T332",
              "entity": "轻、中度",
              "entity_type": "Level",
              "start_idx": 159,
              "end_idx": 163
            },
            {
              "entity_id": "T333",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 163,
              "end_idx": 168
            },
            {
              "entity_id": "T334",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 163,
              "end_idx": 164
            },
            {
              "entity_id": "T335",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 209,
              "end_idx": 212
            },
            {
              "entity_id": "T336",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 221,
              "end_idx": 224
            },
            {
              "entity_id": "T337",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 219,
              "end_idx": 221
            },
            {
              "entity_id": "T338",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 268,
              "end_idx": 273
            },
            {
              "entity_id": "T339",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 278,
              "end_idx": 282
            },
            {
              "entity_id": "T340",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 289,
              "end_idx": 294
            },
            {
              "entity_id": "T341",
              "entity": "监测血糖",
              "entity_type": "Test_items",
              "start_idx": 307,
              "end_idx": 311
            },
            {
              "entity_id": "T342",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 316,
              "end_idx": 318
            },
            {
              "entity_id": "T343",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 329,
              "end_idx": 332
            },
            {
              "entity_id": "T345",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 26
            },
            {
              "entity_id": "T346",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 261,
              "end_idx": 264
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R82",
              "head_entity_id": "T345",
              "tail_entity_id": "T311"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R83",
              "head_entity_id": "T312",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R84",
              "head_entity_id": "T314",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R85",
              "head_entity_id": "T316",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R86",
              "head_entity_id": "T320",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R87",
              "head_entity_id": "T323",
              "tail_entity_id": "T322"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R88",
              "head_entity_id": "T325",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R89",
              "head_entity_id": "T326",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R90",
              "head_entity_id": "T327",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R91",
              "head_entity_id": "T330",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R92",
              "head_entity_id": "T331",
              "tail_entity_id": "T333"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R93",
              "head_entity_id": "T334",
              "tail_entity_id": "T333"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R94",
              "head_entity_id": "T343",
              "tail_entity_id": "T340"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "④目前，所有磺脲类药物均未被中国食品药品监督管理局(CFDA)批准用于妊娠、儿童和青少年患者。",
          "start_idx": 341,
          "end_idx": 388,
          "entities": [
            {
              "entity_id": "T344",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 11
            }
          ],
          "relations": []
        }
      ]
    }
  ]
}